Terry Mahn Esq.

Fish & Richardson P.C.
Mahn, Terry G.

Terry G. Mahn is Managing Principal of Fish & Richardson's Washington, D.C., office, and the Regulatory and Government Affairs Practice Group Leader, and serves as a member of the advisory board of Law's Pharmaceutical Law & Industry Report. His practice is primarily before the Federal Communications Commission (FCC) and U.S. Food and Drug Administration (FDA) with emphasis on complex product authorizations.

Mr. Mahn's FDA practice involves pharmaceutical and medical device approvals with special emphasis on drug exclusivities and patent protections under Hatch-Waxman and the Biologics Price Competition and Innovation Act for biosimilars. He provides advice and counseling to clients on the scope and applications of 271(e)(1) safe harbor; Orange Book practice and patent litigation under 271(e)(2); marketing exclusivities for pioneers and generics; and patent term extensions.

His FDA experience spans a wide range of products, including small molecule drugs, biologics, and medical devices. His client work includes gene and cell therapies, antihypertensives, ophthalmics, anti-inflammatories, immunologics, antibiotics, anti-anxieties, hormone therapies, and medical gases. Device work includes research and screening technologies, dialysis, dental devices, implants, imaging agents, medical telemetry, PARS, catheters, cardiovascular devices, microwave therapies, pressure monitors, oximeters, and various types of drug delivery technologies. He is also experienced in x-ray, MRI, PET, and medical lasers.

Mr. Mahn received his B.S. from the University of Michigan and his J.D. from Catholic University of America, Columbus School of Law.


Предлагаем best-mining.com.ua у нашего менеджера.